Anti-SSA antibodies are present in immunoglobulin preparations

Transfusion

Volumn 55, Issue 4, 2015, Pages 832-837

  Van Der Molen, Renate G ^a   Hamann, Dörte ^b   Jacobs, Joannes F M ^a   Van Der Meer, Arnold ^a   De Jong, Jan ^b   Kramer, Christine ^c   Strengers, Paul F W ^c   Van Der Meer, Jos W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sanquin Diagnostiek   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; IMMUNOGLOBULIN G; RO ANTIBODY; AUTOANTIGEN; IMMUNOGLOBULIN; RIBONUCLEOPROTEIN; SS-A ANTIBODIES; SS-A ANTIGEN;

ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CASE REPORT; COMMON VARIABLE IMMUNODEFICIENCY; DISCOID LUPUS ERYTHEMATOSUS; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOLOGICAL PROCEDURES; SKIN BIOPSY; ADULT; AGED; BLOOD; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, DISCOID; MALE; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; BLOOD DONORS; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, DISCOID; MALE; MIDDLE AGED; RIBONUCLEOPROTEINS; YOUNG ADULT;

EID: 84926454833     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12922     Document Type: Article

References (24)

1. von Muhlen CA, Tan EM,. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995; 24: 323-358.
2. Chan EK, Andrade LE,. Antinuclear antibodies in Sjogren's syndrome. Rheum Dis Clin North Am 1992; 18: 551-570.
3. Yamamoto K,. Pathogenesis of Sjogren's syndrome. Autoimmun Rev 2003; 2: 13-18.
4. Kobayashi R, Mii S, Nakano T, et al. Neonatal lupus erythematosus in Japan: a review of the literature. Autoimmun Rev 2009; 8: 462-466.
5. Buyon JP, Clancy RM, Friedman DM,. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol 2009; 5: 139-148.
6. Fritzler MJ, Pauls JD, Kinsella TD, et al. Antinuclear, anticytoplasmic, and anti-Sjogren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 1985; 36: 120-128.
7. Hornberger LK, Al Rajaa N,. Spectrum of cardiac involvement in neonatal lupus. Scand J Immunol 2010; 72: 189-197.
8. Strickland RW, Tesar JT, Berne BH, et al. The frequency of sicca syndrome in an elderly female population. J Rheumatol 1987; 14: 766-771.
9. Kazatchkine MD, Bellon B, Kaveri SV,. Mechanisms of action of intravenous immunoglobulin (IVIG). Mult Scler 2000; 6 (Suppl 2): S24-26; discussion S33.
10. Sherer Y, Levy Y, Shoenfeld Y,. IVIG in autoimmunity and cancer-efficacy versus safety. Expert Opin Drug Saf 2002; 1: 153-158.
11. Eijkhout HW, van den Broek PJ, van der Meer JW,. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 2003; 61: 213-217.
12. Salomonsson S, Dorner T, Theander E, et al. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 2002; 46: 1233-1241.
13. van der Meer JW, van Beem RT, Robak T, et al. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura. Vox Sang 2011; 101: 138-146.
14. Terpstra FG, Parkkinen J, Tolo H, et al. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. Vox Sang 2006; 90: 21-32.
15. Sonesson SE, Salomonsson S, Jacobsson LA, et al. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004; 50: 1253-1261.
16. Pierce LR, Jain N,. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003; 17: 241-251.
17. Sherer Y, Levy Y, Shoenfeld Y,. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford) 2000; 39: 421-426.
18. Berkowitz RL, Kolb EA, McFarland JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 2006; 107: 91-96.
19. Omwandho CO, Gruessner SE, Roberts TK, et al. Intravenous immunoglobulin (IVIG): modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders. Clin Chem Lab Med 2004; 42: 359-370.
20. Pisoni CN, Brucato A, Ruffatti A, et al. Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum 2010; 62: 1147-1152.
21. Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010; 62: 1138-1146.
22. Desborough MJ, Miller J, Thorpe SJ, et al. Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature. Transfus Med 2014; 24: 219-226.
23. Sakem B, Matozan K, Nydegger UE, et al. Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations. Isr Med Assoc J 2013; 15: 617-621.
24. Mainra R, Xu Q, Chibbar R, et al. Severe antibody-mediated rejection following IVIG infusion in a kidney transplant recipient with BK-virus nephropathy. Transpl Immunol 2013; 28: 145-147.